🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

JCO Global Oncology just published Competencies for Global Oncology Training for understanding and defining disparities - Maite Bourlon ASCO JCO Global Oncology oncodaily.com/51005.html #Cancer #GlobalOncologyTraining #GlobalHealth #Oncology #LMICs #OncoDaily #WWCC

El Instituto Nacional de Cancerología Cumple 78 Años de Atender a la Población nmas.com.mx/foro-tv/progra… vía NMás

Patients presents with vomiting, homonymous visual field defects and headache What is the diagnosis? #MEDHM #MedX Dr Ihab Suliman

help.x.com/es/search-resu…

help.x.com/de/search-resu…

👇👇💪💯💯

15-Minute Morning Workout

In 2022, an estimated 2.6 million new cancer cases and 2.1 million cancer deaths occurred in adults aged 80 years or over. There's a great variation in age-standardised incidence and mortality rates across world regions and income level. authors.elsevier.com/c/1k9y~6gzKuTt…

16 Días de Activismo contra la Violencia de Género

I’m going to be a Gastroenterologist!!!💩 Can’t wait to continue my journey at my top choice UVA GI Hep in my dream specialty alongside my husband! #GImatch #Match2025

idx.dev/blog/post/tips…

Abs workout 🔥💪🏾

Integrating and developing AI and Deep Learning tools in Lung Cancer I3LUNG @. Amazing work lead by arsela prelaj #ITCD2025

Androgen receptor (AR) in non-prostatic cancers: an untapped target? AR plays a key role beyond prostate cancer, yet its therapeutic potential remains underexplored. Targeting AR could help overcome therapy resistance. 📖 Nature Reviews Cancer 🔗 DOI: 10.1038/s41568-024-00772-w

Whisky, Relojes y Arte: Inversiones No Convencionales que Podrían Hacerte Rico (o Arruinarte) Es mi podcast 🎙️ especial de hoy. ¡Escúchenlo aquí! 👇 open.spotify.com/episode/0lXao3…

🚨 ¡Confirmado! 📍 Cancún Center 📅 24–27 septiembre 2025 🎓 Congreso Nacional de Oncología 🌐 Congreso Internacional #RumboACancún #CongresoSMeO2025 #SMeO2025 #CancerResearch

Results from OptiTROP-B01 out in Nature Medicine. The TROP2-ADC sacituzumab tirumotecan improved PFS and OS in highly pretreated mTNBC, irrespective of Trop2 exp. Results similar to ASCENT. Approved in China, may soon also reach the west (4th topo1 ADC). nature.com/articles/s4159…

MSI-H/dMMR cancers: biology, impact & therapeutic evolution. A distinct, immunogenic subtype: -High ICI sensitivity -Lynch syndrome link -Key in CRC, endometrial & more -Now targeted in early stages too Histology-agnostic precision at its best. 📖 NatureRevClinOncol DOI 👉🏻

myvidster.com/thankyou.htm